IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%

Shares of IRIDEX Corporation IRIX have declined 15.2% since the company reported its earnings for the quarter ended July 4, 2026. This compares to the S&P 500 index’s 1% decline over the same time frame. Over the past month, the stock has declined 16% against the S&P 500’s 3.5% gain.

IRIDEX incurred a second-quarter 2026 net loss of 7 cents per share, wider than a loss of 6 cents per share a year earlier. 

Revenues of $12.6 million denoted a 7% decline from $13.6 million in the year-ago quarter, primarily due to lower retina product sales, partly offset by continued growth in glaucoma probe sales. 

Net loss widened to $1.3 million from $1 million a year earlier. Gross profit declined to $4.3 million from $4.7 million, while gross margin was relatively stable at 34.2% versus 34.5%. Operating expenses decreased 5% year over year to $5.3 million. Adjusted EBITDA was a loss of $0.4 million compared with positive adjusted EBITDA of $0.02 million in the prior-year period.

IRIDEX Corporation Price, Consensus and EPS Surprise

IRIDEX Corporation price-consensus-eps-surprise-chart | IRIDEX Corporation Quote

Glaucoma Growth Offsets Retina Weakness

Cyclo G6 product family revenues increased 19% year over year to $3.9 million from $3.3 million, supported by strong probe demand. IRIDEX sold 17,700 Cyclo G6 probes, up roughly 35% from 13,100 a year earlier, reflecting increased utilization of the G6 platform. However, Cyclo G6 laser system sales declined to 18 units from 35, with management citing order timing in Europe, the Middle East and Africa and competitive pressure on new console placements. Retina product revenues fell to $6.5 million from $8 million, while other revenues remained essentially flat at $2.2 million.

Balance Sheet Update

IRIDEX ended the quarter with cash and cash equivalents of $4.7 million, down from $6 million as of Jan 3, 2026. As of July 4, inventories stood at $9.8 million, up from $7.9 million at Jan. 3, 2026, while total assets declined to $27.3 million from $29.2 million.

Total stockholders’ equity declined to $3.6 million from $4.9 million over the same period.

Management Highlights Cost and Commercial Initiatives

Management characterized the quarter as an important step in IRIDEX's efforts to reshape its financial profile, pointing to positive cash flow, cost controls and improved working-capital management. The company is targeting greater G6 utilization by focusing on existing accounts with moderate usage and high-volume glaucoma practices that have not yet incorporated MicroPulse therapy. Management also cited Medicare local coverage determination tailwinds and higher U.S. average selling prices as contributors to glaucoma momentum.

For retina, management said underlying demand remained intact despite weaker reported sales. The company expects the second half of 2026 to deliver low-single-digit retina growth, aided by progress on international regulatory approvals, U.S. promotional activity and improved commercial execution. Management also expects low-double-digit glaucoma growth in the second half, although some second-quarter probe demand reflected pre-orders associated with anticipated regulatory blackout periods.

International Factors Pressure Headline Results

The revenue decline was concentrated in retina and reflected international commercial transitions and regulatory-related issues. Middle East disruptions weighed on sales, while China was affected by regulatory constraints and distributors working through existing inventory. Gross-margin benefits from higher-margin glaucoma probes were largely offset by softer retina system margins and other cost pressures. Meanwhile, lower general and administrative expenses stemming from the company's administrative-function transfer initiative helped reduce overall operating expenses.

2026 Outlook Reaffirmed

IRIDEX reaffirmed full-year 2026 revenue guidance of $51-$53 million. Management noted that the outlook excludes Middle East revenues and represents roughly 1-5% pro forma growth from 2025 when prior-year Middle East revenues are excluded. The company also maintained its expectation for adjusted operating expenses, excluding depreciation and amortization and stock-based compensation, of $19-$19.5 million.

Other Developments

IRIDEX continued its restructuring efforts, including relocating its headquarters to a lower-cost facility and shifting production to lower-cost third-party contract manufacturers. To protect international supply during the transition and potential regulatory blackout periods, the company is building additional inventory. Management expects the restructuring initiatives to improve operating efficiency and support gross-margin improvement, although the inventory investment is expected to reduce cash on hand through 2026 before reversing as inventory levels are worked down in 2027.

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research